mRNA Synthesis Raw Material Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

mRNA Synthesis Raw Material Market Forecast 2024-2028

The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028. 

Advancements in mRNA technology are propelling the global mRNA synthesis raw material market forward, reshaping healthcare and biotechnology. Continuous evolution in synthesis processes is unleashing unprecedented potential for therapeutic, vaccine, and diagnostic development. Innovations enhance synthesis methods, purification techniques, and delivery systems, boosting mRNA-based product efficiency, safety, and efficacy. Purification advances ensure high-quality, contaminant-free mRNA molecules, enhancing product safety. Breakthroughs in delivery systems, like lipid nanoparticles, enable targeted mRNA delivery, overcoming stability and immunogenicity challenges. Increasing mRNA technology adoption across healthcare and biotech fuels raw material demand. Growing investment from governments, biopharmaceutical firms, and research institutions is expected to further drive market growth during the forecast period.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Application, End-user, and Geography Analysis

The mRNA synthesis raw material market is a vital component in the development of mRNA-based therapeutics and vaccines. Key players in the biotech and pharmaceutical sectors, in compliance with regulatory frameworks such as those set by the US FDA and WHO, rely on these raw materials for drug discovery, vaccine development, and therapeutics manufacturing. These materials, including capping agents and IVT mRNA produced using CleanCap technology from companies like TriLink, are essential for mRNA technology platforms. They cater to a wide range of applications, from combating infectious diseases like tuberculosis to addressing chronic diseases such as cancer and cardiovascular diseases. As demand surges for RNA-based vaccines like mRNA-1273, the market presents significant revenue growth opportunities, particularly in the biopharmaceutical sector. Moreover, advancements in personalized medicine and the continuous expansion of research and development activities underscore the importance of high-quality raw materials provided by Life Sciences Tools & Services companies in driving innovation and addressing manufacturing complexities.

Application Analysis 

The market share growth by the vaccine production segment will be significant during the forecast period. The rising use of these raw materials has revolutionized mRNA-based vaccine production, offering a groundbreaking approach to developing and manufacturing vaccines against infectious diseases. mRNA vaccines have gained significant attention due to their rapid development timelines, scalability, and potential for inducing robust immune responses. 

Get a glance at the market contribution of various segments Download PDF Sample

The vaccine production segment was the largest and was valued at USD 1.62 billion in 2018. Thermo Fisher Scientific Inc. is a premier provider of life sciences tools and services, offering a diverse range of mRNA synthesis reagents and kits tailored to vaccine production needs. These products streamline mRNA synthesis, purification, and analysis processes, enabling swift development and scaling of mRNA-based vaccines. Collaborating with Thermo Fisher grants vaccine manufacturers access to top-tier raw materials and technical assistance, expediting the production of vaccines for diseases like COVID-19, influenza, and Zika virus. Merck KGaA is also pivotal, supplying essential raw materials, including nucleotides, enzymes, and purification systems, along with custom manufacturing services. Through partnerships with vaccine manufacturers and academic researchers, Merck KGaA contributes to mRNA vaccine innovation, bolstering responses to emerging infectious threats. These dynamics are poised to propel growth in the segment during the forecast period. 

End-user Analysis 

The burgeoning employment of mRNA synthesis raw materials in biopharmaceutical and pharmaceutical companies is propelled by the escalating interest in mRNA-based therapies and vaccines. This surge reflects a paradigm shift in drug development, with mRNA technology offering unprecedented opportunities for precision medicine and rapid response to emerging infectious diseases. Key vendors, including Thermo Fisher Scientific Inc., Merck KGaA, and F. Hoffmann La Roche Ltd play pivotal roles in this landscape. They supply a spectrum of reagents and kits essential for mRNA synthesis, purification, and analysis. Such raw materials are critical for the efficient production of mRNA molecules tailored for therapeutic interventions, ranging from cancer immunotherapy to infectious disease vaccines. As research and development efforts in mRNA therapeutics continue to advance, these vendors are poised to remain integral partners, ensuring the availability of high-quality raw materials to support the progression of mRNA-based pharmaceuticals from the laboratory to clinical applications. All these factors are expected to drive the growth of the biopharmaceutical and pharmaceutical companies segment of the market during the forecast period.

The rising utilization of mRNA synthesis raw materials in Contract Research Organizations (CROs) and CMOs underscores the expanding landscape of mRNA-based therapeutics and vaccines. CROs and CMOs are increasingly becoming integral partners in the development and production of these innovative biopharmaceuticals, offering specialized expertise and infrastructure to meet the growing demand. Companies supplying raw materials play a crucial role in supporting these organizations as they navigate the complexities of messenger ribonucleic acid drug development and manufacturing. For instance, Merck KGaA provides a range of high-quality raw materials for messenger ribonucleic acid synthesis, along with custom manufacturing services, enabling CROs and CMOs to access specialized reagents and expertise to accelerate their mRNA-based programs. Therefore, as CROs and CMOs continue to play a vital role in the translation of messenger ribonucleic acid therapeutics from preclinical development to clinical trials and commercialization, partnerships with vendors supplying raw materials will be instrumental in driving innovation and meeting the growing demand for these transformative therapies in the biopharmaceutical industry. These factors are expected to drive the growth of the CROs and CMOs segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers that will shape the market during the forecast period. The messenger ribonucleic acid synthesis raw material market in North America is experiencing dynamic growth driven by the burgeoning interest in mRNA-based therapeutics, vaccines, and diagnostics. With North America being a hub for biopharmaceutical innovation and home to numerous leading biotech and pharmaceutical companies, the region is witnessing substantial investment and research focus in mRNA technology. This surge in interest is propelled by the remarkable potential of mRNA-based approaches in addressing a wide range of diseases, including cancer, infectious diseases, and genetic disorders. As a result, there is a growing demand for high-quality raw materials essential for mRNA synthesis processes.

In addition, technological advancements in messenger ribonucleic acid synthesis, delivery systems, and formulation techniques are expanding the scope of mRNA-based applications, creating a need for specialized raw materials to meet the stringent quality and purity requirements of mRNA synthesis processes. Government support and funding, coupled with public-private partnerships and incentives, are fostering innovation and investment in mRNA research and development, further driving market opportunity. Additionally, strategic collaborations and partnerships between biopharmaceutical companies, academic institutions, and raw material suppliers are facilitating knowledge sharing, technology transfer, and the development of customized raw materials tailored to specific mRNA-based applications. Such factors are expected to drive the regional market growth during the forecast period. 

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

BioNTech SE, BOCSCI Inc - The company offers mRNA synthesis raw material such as uridine mRNA, which aims to provide a highly tumor type specific, off the shelf therapy for cancer patients, particularly those with advanced, hard to treat disease.

Bayer AG, BioNTech SE, BOCSCI Inc., CELONIC Group, Corden Pharma International GmbH, Creative Biolabs, CureVac AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, HONGENE, Jena Bioscience GmbH, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, New England Biolabs Inc., Pfizer Inc., Promega Corp., Samsung Electronics Co. Ltd., Thermo Fisher Scientific Inc., and Yeasen Biotechnology Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is driven by the escalating demand for mRNA-based therapeutics and vaccines, propelled by advancements in drug discovery and vaccine development. Biotech and pharmaceutical companies, adhering to regulatory frameworks set by organizations like the US Food & Drug Administration (US FDA) and WHO, are increasingly investing in technology platforms for therapeutics manufacturing. Key trends include the rise of RNA-based vaccines like mRNA-1273 and the growing focus on personalized medicine. However, challenges such as manufacturing complexities and regulatory compliance pose hurdles to market growth despite the significant revenue opportunities presented by adjacent markets and continuous research and development efforts. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Drivers

The advantages of mRNA vaccines are notably driving market growth. The advantages of mRNA vaccines are propelling the growth of the global mRNA synthesis raw material market. The vaccines offer rapid development timelines, scalability, and adaptability, bypassing the need for viral culture. This scalability is crucial during public health emergencies, such as the COVID-19 pandemic. Such technology allows for swift modifications to vaccine formulations, addressing evolving viral variants.

Moreover, with fewer adverse reactions in clinical trials compared to traditional vaccines, mRNA vaccines show promise in preventing various infectious diseases. As the healthcare sector embraces vaccines, the demand for raw materials like nucleotides and enzymes is surging. Market players are well-positioned to capitalize on these opportunities, driving further growth in the market during the forecast period.

Significant Trends

Increasing R&D investments by pharmaceutical and biopharmaceutical companies is an emerging trend shaping market growth. The rising prevalence and incidence of various chronic diseases, such as diabetes, asthma, cancer, heart diseases, arthritis, cystic fibrosis, and dementia, have increased the need for developing drugs for treatment. This, in turn, increases the demand for producing vaccines and therapeutics. Pharmaceutical and biopharmaceutical companies are strengthening their product pipeline by developing advanced innovative drugs for therapeutic areas, such as immunology, cancer, and infectious diseases. 

Further, pharmaceutical companies majorly spend approximately 65% and 35% of their revenue on discovery, early-stage development, and late-stage development, respectively. There is a need for such raw materials for pharmaceutical companies to develop a strong pipeline. The elaborative R&D process for product development has increased the demand for advanced software to accelerate the R&D process. This, in turn, is expected to drive the growth of the market during the forecast period.

Major Challenges

The complexity of mRNA synthesis and purification processes is a significant challenge hindering market growth. The complexity of mRNA synthesis and purification processes presents a significant obstacle to the expansion of the global mRNA synthesis raw material market. These processes involve intricate steps and specialized reagents, enzymes, and purification techniques, adding complexity and cost to production. Manufacturers must invest in advanced technologies and quality control measures, raising production costs and potentially deterring smaller firms and academic institutions.

Moreover, mRNA purification requires precise separation techniques to remove impurities effectively, posing technical challenges in achieving high yields and purity levels. Variations in purification protocols further complicate procurement and usage. These challenges impede the widespread adoption of mRNA-based technologies, potentially hindering market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Application Outlook
  • Vaccine production
  • Therapeutics production
  • Others

• Application Outlook
  • Large Enterprise
  • Small and Medium Enterprise

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Market Analyst Overview 

The market is experiencing significant growth driven by advancements in mRNA technology platforms and increasing demand for personalized medicine and gene therapies. Government agencies and RNA centers, including the US FDA and the National Institute of Allergy and Infectious Diseases, play vital roles in establishing regulatory frameworks and promoting awareness about healthcare technology. However, manufacturing complexities and strict regulations pose challenges, particularly in developing nations. To address these challenges, the industry is focusing on flexible, durable, and cost-effective production methods alongside advancements in medical technology.

Furthermore, the pharmaceutical sector, along with academic institutions and CROs, is driving revenue growth in the market, with a focus on therapeutic sector applications like early detection and cardiovascular diseases. Overall, the market offers immense opportunities for innovation and growth, supported by the increasing demand for innovative products and the personalization of healthcare services. Further, the mRNA synthesis raw material market is witnessing significant growth, driven by advancements in therapeutics manufacturing and the increasing demand for personalized medicine.

Additionally, regulatory bodies like the US FDA and the World Health Organization (WHO) play crucial roles in ensuring compliance with standards in the production of in vitro transcribed (IVT) mRNA, particularly for diseases like tuberculosis. Academic institutions, CROs, and CMOs contribute to market segment growth by providing Life Sciences Tools & Services tailored to meet evolving needs. However, challenges such as problems with costs and regulatory frameworks persist, necessitating facility customization and innovative approaches to boost the supply of raw materials. Overall, the market presents opportunities for enhancing service quality and delivering fresh ideas for the personalization of healthcare services to the general population.

Market Scope
Report Coverage	Details
Page number	170
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 4.93%
Market Growth 2024-2028	USD 776.45 million
Market structure	Fragmented
YoY growth 2023-2024(%)	4.34
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 34%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Bayer AG, BioNTech SE, BOCSCI Inc., CELONIC Group, Corden Pharma International GmbH, Creative Biolabs, CureVac AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, HONGENE, Jena Bioscience GmbH, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, New England Biolabs Inc., Pfizer Inc., Promega Corp., Samsung Electronics Co. Ltd., Thermo Fisher Scientific Inc., and Yeasen Biotechnology Co. Ltd.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch